COQMITMEL

Mouse Model of CoQ deficiency: pathogenesis and treatment

 Coordinatore UNIVERSIDAD DE GRANADA 

 Organization address address: CUESTA DEL HOSPICIO SN
city: GRANADA
postcode: 18071

contact info
Titolo: Ms.
Nome: María Dolores
Cognome: Suárez Ortega
Email: send email
Telefono: +34 958 240824
Fax: +34 958 240886

 Nazionalità Coordinatore Spain [ES]
 Totale costo 100˙000 €
 EC contributo 100˙000 €
 Programma FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
 Code Call FP7-PEOPLE-2009-RG
 Funding Scheme MC-IRG
 Anno di inizio 2009
 Periodo (anno-mese-giorno) 2009-11-01   -   2013-10-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    UNIVERSIDAD DE GRANADA

 Organization address address: CUESTA DEL HOSPICIO SN
city: GRANADA
postcode: 18071

contact info
Titolo: Ms.
Nome: María Dolores
Cognome: Suárez Ortega
Email: send email
Telefono: +34 958 240824
Fax: +34 958 240886

ES (GRANADA) coordinator 100˙000.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

   deficiency    coq    supplementation    mice    enzyme    pdss    clinical    treatment    found    gene    function    mitochondrial    knockin    coenzyme    patients    pathological    mutation   

 Obiettivo del progetto (Objective)

'Coenzyme Q10 (CoQ10) deficiency is an autosomal recesive disorder where the encephalomyopathy and nephropathy seems to be the most important clinical presentations. Some patients respond to CoQ10 supplementation but others do not. In my Postdoctoral stay in Columbia University I identified the first mutation in PDSS2, which encoded the protein responsible for the syntesis of decaprenyl chain. Moreover, I have studied the pathological consequences associated to CoQ10 deficiency in culture fibroblasts with mutations in PDSS2, COQ2, ADCK3 and COQ9. The results show that mitochondrial bioenergetic, the increase of oxidative stress and the defect in de novo pathway for pyrimidines can be the main pathological mechanisms associated to CoQ10 deficiency. However, the tissue specificity need to be investigated since CoQ10 is present in all cells types and is critical for mitochondrial function. In addition, potential treatment need to be tested. Then, I propose: 1) Generate COQ9 knockin mice. Dra. Rahman’s Group has recently found a mutation in this gene in a patient with CoQ10 deficiency. This gene encode Coq9, an enzyme involved in ubiquinone biosynthesis. However, the function of this enzyme is still unkown and I will study it; 2) Charaterize COQ9 knockin mice including behevioural, clinical, hitological-morphological, physiological, bioquemical and genetical studies; 3) Develop and apply different therapeutical strategies: a) Early an late onset treatment with CoQ10; and b) antioxidant strategy (melatonin administration). The results will be essential to undertand and treat the pathegenesis of CoQ10 deficiency, as well as other primary mitochondrial disorders. Likewise, the results can be important in the treatment of neurodegenerative diseases or aging, since CoQ10 supplementation is been used in clinical trials of parkinson´s patients or it is recommended as nutritional suplemmentation in the elderly population.'

Introduzione (Teaser)

European research has straightened out some of the controversy surrounding a supplement found in many health food store shelves, coenzyme Q10 (CoQ10).

Altri progetti dello stesso programma (FP7-PEOPLE)

STAMYEV (2014)

Structural and biochemical basis of protein amyloid evolution

Read More  

BATTINSITU (2013)

"In-situ Nuclear Magnetic Resonance Investigation of the Critical Failure Mechanism of Lithium Batteries: Toward safer, highly reliable and energy dense storage."

Read More  

ONCOGENIC SPLICING (2008)

Characterizing the oncogenic properties and target genes of the splicing factor protooncogene SF2ASF

Read More